Sanofi India Limited

Sanofi India Board Approves FY25 Audited Results, Recommends Final Dividend of ₹48/Share

Sanofi India's Board approved audited FY25 results, recommending a final dividend of ₹48 per share, bringing the total to ₹123. Key appointments include Mrs. Rajani Kesari as Independent Director (effective April 1, 2026) and Ms. Sudipta Chakraborty as Whole-time Director (effective March 1, 2026). Mr. Rodolfo Hrosz resigned as Non-Executive Director.

Sanofi India Recommends Final Dividend of ₹48; Total Dividend ₹123 for FY25

Sanofi India's Board approved FY25 Audited Financial Results and recommended a final dividend of ₹48 per share, bringing the total dividend for FY25 to ₹123 per share. The company also announced key director appointments: Mrs. Rajani Kesari as Independent Director from April 1, 2026, and Ms. Sudipta Chakraborty as Whole-time Director from March 1, 2026. Mr. Rodolfo Hrosz resigned as Non-Executive Director, effective February 28, 2026.

Sanofi India Recommends Final Dividend of ₹48, Total Dividend ₹123 for FY25

Sanofi India's Board approved FY25 audited results and recommended a final dividend of ₹48, bringing the total dividend to ₹123 per share. The company appointed Mrs. Rajani Kesari as Independent Director and Ms. Sudipta Chakraborty as Whole-time Director. Mr. Rodolfo Hrosz resigned as Non-Executive Director.

Sanofi India faces ₹2.37 Crore tax demand from Tiruvallur Commercial Tax Officer

Sanofi India Limited received an order for FY 2021-22 determining a total tax demand of ₹2.37 crore. This includes ₹1.34 crore tax, ₹0.89 crore interest, and ₹0.13 crore penalty. The demand is related to Input Tax Credit eligibility. The company plans to appeal the order.

Sanofi India to Hold Analyst Call on Feb 26 for FY25 Audited Results

Sanofi India Limited will host an investor and analyst call on February 26, 2026, to discuss audited financial results for the quarter and year ended December 31, 2025. The call is scheduled from 4:00 PM to 5:00 PM IST. Pre-registration is mandatory and closes at 12:00 PM on Feb 26, 2026.

Sanofi India Senior Management Change: Suresh Babu Resigns as Sales Head

Mr. Suresh Babu, Sales & Customer Engagement Head – Diabetes at Sanofi India Limited, has resigned. His resignation is effective February 12, 2026, as he seeks opportunities outside Sanofi. He will cease to be a Senior Management Personnel on this date.

Sanofi India Limited Publishes Notice to Shareholders in Business Standard and Sakal

Sanofi India Limited published a Notice to Shareholders on January 9, 2026, in the Business Standard (English) and Sakal (Marathi) newspapers. This is a routine regulatory filing informing shareholders of published information.

Sanofi India Ltd. Files SEBI Regulation 74(5) Certificate for Dec 2025 Quarter

Sanofi India Limited submitted a certificate under SEBI Regulation 74(5) for the quarter ended December 31, 2025. The RTA, MUFG Intime India, confirmed the processing of dematerialisation requests and updates to the register of members.

Sanofi India receives order for ₹2.86 Crore tax demand and penalty

Sanofi India Limited received an order from CGST & Central Excise, Mumbai, for FY 2018-19 to FY 2022-23. The order includes a tax demand of ₹1,43,49,690, a penalty of ₹1,43,49,690, and interest for wrong availment/utilization of Input Tax Credit. The company intends to appeal the order.

Sanofi India Limited: Trading Window Closed for Q4 FY25 Results Declaration

Sanofi India Limited will close its trading window from January 1, 2026, until 48 hours after the announcement of financial results for the quarter and year ending December 31, 2025. This is a standard procedure for the declaration of financial results.

Sanofi India Limited Announces Special Window for Physical Share Transfer Requests

Sanofi India Limited is opening a special window for re-lodging transfer requests for physical shares. This follows a SEBI circular dated July 2, 2025, and was published in Business Standard and Sakal on December 25, 2025.

Sanofi India receives ₹24.10 Lakh tax demand order for FY19

Sanofi India Limited received a tax demand order of ₹24.10 Lakh for FY19 from Gujarat State Tax authorities. The demand includes ₹12.96 Lakh tax, ₹9.85 Lakh interest, and ₹1.30 Lakh penalty related to excess ITC claims. The company plans to appeal the order.

Sanofi India receives tax order for ₹14.29 Lakhs for FY21-22

Sanofi India Limited received a tax order for FY 2021-22 from Delhi authorities, totaling ₹14.29 Lakhs. This includes tax, interest, and penalty. The company plans to appeal the order.

Sanofi India receives order for ₹35.6 Lakhs tax, interest, and penalty for FY19

Sanofi India received an order from Gujarat tax authorities for FY19, demanding ₹35.6 Lakhs. This includes ₹10.8 Lakhs tax, ₹14 Lakhs interest, and ₹10.8 Lakhs penalty due to GST compliance issues. The company plans to appeal the decision.

Sanofi India Approves Appointment of Deepak Arora as Director and MD

Sanofi India Limited's postal ballot concluded with overwhelming support for Mr. Deepak Arora's appointment as Director and Managing Director. Both resolutions passed with high majorities, with 99.84% in favour of his appointment as Director and 94.70% in favour of his appointment as Managing Director.

Sanofi India Limited informs about Newspaper Publication of Postal Ballot Notice

Sanofi India Limited announced a newspaper publication regarding the dissemination of the Notice of Postal Ballot to the Shareholders for the appointment of Mr. Deepak Arora as the Director and Managing Director.

Sanofi India: Postal Ballot for Appointment of Mr. Deepak Arora as Director & MD

Sanofi India seeks shareholder approval via postal ballot for appointing Mr. Deepak Arora as Director & MD, with e-voting from Nov 18 to Dec 17, results by Dec 19.

Sanofi India Q3 2025 Earnings Call Transcript Released; Interim Dividend Declared & Business Transformation Progress

Sanofi India released Q3 2025 earnings call transcript, announced a ₹75 interim dividend, and detailed progress on its business transformation focused on diabetes, showing improved margins and growth.

Sanofi India declares ₹75 Interim Dividend; Record Date Fixed

Sanofi India declares an interim dividend of ₹75 per share with a face value of ₹10. Record date is set as 7th November 2025.

Sanofi India Limited Announces Upload of Investor/Analyst Call Video Recording

Sanofi India Limited uploaded the video recording of the Investor/Analysts Call held on 29th October 2025, to discuss the Un-audited Financial Results for the quarter and nine months ended 30th September 2025.

Sanofi India publishes financial results for Q3 and nine months ended September 2025

Sanofi India Limited announced the newspaper publication of its financial results for the quarter and nine months ended 30th September 2025 in Business Standard and Sakal on October 30, 2025.

Sanofi India Investor/Analysts Call Presentation on Q3 2025 Results

Sanofi India to conduct an investor call on Q3 2025 results. Highlights include business model transformation, growth in domestic sales, focus on insulin franchise, and improved profitability.

Sanofi India approves Q3 FY25 results, declares ₹75 interim dividend with Nov 7 record date

Sanofi India approved Q3 FY25 results, reporting ₹4,754 crore revenue and ₹760 crore profit from continuing operations. It declared an interim dividend of ₹75 per share with November 7, 2025, as the record date.

Sanofi India Board Approves Q3 FY25 Results, Declares Interim Dividend of ₹75 per Share

Sanofi India's board approved Q3 and nine-month FY25 results. Revenue declined, but nine-month profit from continuing operations increased. An interim dividend of ₹75 per share was declared.

Sanofi India appoints Deepak Arora as new MD; Rachid Ayari steps down as Interim MD

Sanofi India Limited appointed Mr. Deepak Arora as its new Managing Director for three years, effective October 27, 2025. Mr. Rachid Ayari stepped down as Interim MD, continuing as Whole-time Director and CFO.

Sanofi India Appoints Deepak Arora as Managing Director; Rachid Ayari Steps Down as Interim MD

Sanofi India appointed Deepak Arora as MD, effective October 27, 2025, for three years, subject to approvals. Rachid Ayari stepped down as Interim MD, effective October 26, 2025, but continues as CFO.

Sanofi India appoints Deepak Arora as Managing Director

Sanofi India appoints Deepak Arora as Managing Director effective October 27, 2025, subject to approvals. Rachid Ayari steps down as Interim MD but continues as CFO.

Sanofi India Appoints Deepak Arora as New MD; Rachid Ayari Steps Down as Interim MD

Sanofi India's Board appointed Deepak Arora as the new Managing Director for three years, effective October 27, 2025. Interim MD Rachid Ayari stepped down but continues as Whole-time Director and CFO.

Sanofi India Limited Announces Investor/Analyst Call on 29 Oct 2025

Sanofi India Limited will hold an investor/analyst call on October 29, 2025, to discuss the Un-audited Financial Results for the quarter and nine months ended September 30, 2025.

Sanofi India: Newspaper Publication Regarding Share Relodgement and IEPF Campaign

Sanofi India published a notice regarding share re-lodgement and IEPF campaign in Business Standard and Sakal on October 18, 2025, in compliance with SEBI and MCA directives.

Sanofi India receives CGST & CX order; interest and penalty waived for past periods

Sanofi India received a CGST & CX order, waiving ₹47.52 lakh interest and ₹6.38 lakh penalty for July 2017-March 2020. A demand of ₹13.29 lakh interest and ₹3.75 lakh penalty for April 2020-March 2022 was retained. No material impact reported.

Sanofi India receives Regulation 74(5) compliance certificate for Q2 FY26

Sanofi India received its Regulation 74(5) certificate from its RTA for the quarter ended September 30, 2025, confirming compliance with dematerialisation procedures.

Sanofi India Announces Resignation of Company Secretary and Appointment of New Officer

Sanofi India: Postal Ballot Results - Appointment of Directors Approved

Sanofi India Announces 'Saksham Niveshak' Campaign for Shareholders

Sanofi India Announces Newspaper Publication Regarding Postal Ballot

Sanofi India publishes financial results for quarter, half year ended June 2025

Sanofi India Reports Q1 FY25 Results, Announces Board Changes and Strategic OAD Deal